 | | Vol. 23.23 – 4 July, 2022 |
| |
|
|
| Scientists presented a case of bone marrow failure in a 57-year old man with diffuse large B cell lymphoma (DLBCL)-type Richter transformation receiving tisagenlecleucel in a standard-of-care setting.
[Blood] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors developed and validated an augmented conformal coating (CC) method that achieved hydrogel CCs around islets at physiological pH for improved cytocompatibility, with PEG hydrogels for increased biocompatibility and with fivefold increase in encapsulation throughput for enhanced scalability.
[Science Advances] |
|
|
|
| Scientists investigated the effects of CD34+ cell therapy in patients with heart failure with preserved ejection fraction.
[European Journal of Heart Failure] |
|
|
|
| A new cationic lipid nanoparticle that could efficiently deliver siRNA across blood-brain barrier and target mouse brain was prepared for modulating the tumor microenvironment for glioblastoma multiforme immunotherapy.
[Biomaterials] |
|
|
|
| Researchers evaluated the potential of adeno-associated virus 5 (AAV5)-mediated Id3 gene therapy to treat corneal scarring using an established rabbit in vivo disease model.
[Molecular Therapy] |
|
|
|
| Investigators undertook a retrospective analysis from 1998-2014 of 751 patients with primary plasma cell leukaemi undergoing one of four transplant strategies; single autologous (auto) transplant, single allogeneic (allo) transplant, or a combined tandem transplant either auto-allo or auto-auto.
[Haematologica] |
|
|
|
| The authors demonstrated that multiple intravenous transplantations of allogenic umbilical cord-derived-mesenchymal stromal cells in non-severe COVID-19-induced acute respiratory distress syndrome (ARDS) patients are a safe procedure.
[Stem Cell Research & Therapy] |
|
|
|
| Scientists reported the generation of CAR-T cells using humanized rabbit-derived TCR-like antibodies. The CAR-T cells specifically recognized BRLF1p/MHC molecules and lysed the target cells in an antigen-specific manner in vitro and demonstrated anti-tumor activity in a mouse xenograft model.
[Cancer Science] |
|
|
|
| Researchers compared transplantation outcomes of adult patients with acute myeloid leukemia that underwent CBT in CR1 following 1 versus 2 induction courses.
[Bone Marrow Transplantation] |
|
|
|
| An investigation of donor/recipient chimerism in the population of bone CD34+ sorted cells was performed in 261 allogeneic hematopoietic stem cell transplantation recipients with myeloid malignancies.
[Bone Marrow Transplantation] |
|
|
|
| After daily subcutaneous injection of D-gal (500 mg/kg/d) for 8 weeks, 17-week-old male C57BL/6 J mice were stem cells transplanted by lateral ventricular localization injection.
[Cell Death Discovery] |
|
|
|
| Neural stem cells derived from rhesus monkey embryonic stem cells were resuspended in medium with or without epidermal growth factor (EGF)/basic fibroblast growth factor (bFGF) and xenotransplanted into rat striatum.
[Biochemical and Biophysical Research Communications] |
|
|
|
|
| The authors summarize the key steps in the development of immunotherapies for mesothelioma, focusing on strategies that have led to randomized clinical evaluation and emerging predictors of response.
[Nature Reviews Clinical Oncology] |
|
|
|
| Following a brief history of gene therapy, scientists review current gene therapy products as well as gene therapies that may be approved in the near future.
[Biomedicine & Pharmacotherapy] |
|
|
|
|
| BioRestorative Therapies, Inc. announced that the first patient has been enrolled in the company’s Phase II clinical trial evaluating the safety and preliminary efficacy of BRTX-100, an autologous bone marrow-derived mesenchymal stem cell targeting chronic lumbar disc disease.
[BioRestorative Therapies, Inc. (GlobeNewswire, Inc.)] |
|
|
|
| Enzyvant announced today it is among the National Organization for Rare Disorders 2022 Industry Innovation Awards recipients for the development and FDA approval of RETHYMIC®, a one-time regenerative tissue-based therapy for pediatric congenital athymia.
[Enzyvant (GlobeNewswire, Inc.)] |
|
|
|
|
| November 2 – 4, 2022
Lyon, France |
|
|
|
|
|
| | Georgia Institute of Technology – Atlanta, Georgia, United States |
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
| | Boston Children’s Hospital – Boston, Massachusetts , United States |
|
|
|
| | Duke University – Durham, North Carolina, United States |
|
|
|
| | The University of Arizona – Tucson, Arizona, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
